157 related articles for article (PubMed ID: 38691356)
1. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy.
Westerhoff JM; Daamen LA; Christodouleas JP; Blezer ELA; Choudhury A; Westley RL; Erickson BA; Fuller CD; Hafeez S; van der Heide UA; Intven MPW; Kirby AM; Lalondrelle S; Minsky BD; Mook S; Nowee ME; Marijnen CAM; Orrling KM; Sahgal A; Schultz CJ; Faivre-Finn C; Tersteeg RJHA; Tree AC; Tseng CL; Schytte T; Silk DM; Eggert D; Luzzara M; van der Voort van Zyp JRN; Verkooijen HM; Hall WA
JAMA Netw Open; 2024 May; 7(5):e2410819. PubMed ID: 38691356
[TBL] [Abstract][Full Text] [Related]
2. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
[TBL] [Abstract][Full Text] [Related]
3. First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany.
Klüter S; Katayama S; Spindeldreier CK; Koerber SA; Major G; Alber M; Akbaba S; Debus J; Hörner-Rieber J
Strahlenther Onkol; 2020 Aug; 196(8):691-698. PubMed ID: 32002567
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry.
de Mol van Otterloo SR; Christodouleas JP; Blezer ELA; Akhiat H; Brown K; Choudhury A; Eggert D; Erickson BA; Daamen LA; Faivre-Finn C; Fuller CD; Goldwein J; Hafeez S; Hall E; Harrington KJ; van der Heide UA; Huddart RA; Intven MPW; Kirby AM; Lalondrelle S; McCann C; Minsky BD; Mook S; Nowee ME; Oelfke U; Orrling K; Philippens MEP; Sahgal A; Schultz CJ; Tersteeg RJHA; Tijssen RHN; Tree AC; van Triest B; Tseng CL; Hall WA; Verkooijen HM;
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):867-875. PubMed ID: 34265394
[TBL] [Abstract][Full Text] [Related]
5. First 500 Fractions Delivered with a Magnetic Resonance-guided Radiotherapy System: Initial Experience.
Sahin B; Zoto Mustafayev T; Gungor G; Aydin G; Yapici B; Atalar B; Ozyar E
Cureus; 2019 Dec; 11(12):e6457. PubMed ID: 32025388
[TBL] [Abstract][Full Text] [Related]
6. Online adaptive MR-guided stereotactic radiotherapy for unresectable malignancies in the upper abdomen using a 1.5T MR-linac.
Daamen LA; de Mol van Otterloo SR; van Goor IWJM; Eijkelenkamp H; Erickson BA; Hall WA; Heerkens HD; Meijer GJ; Molenaar IQ; van Santvoort HC; Verkooijen HM; Intven MPW
Acta Oncol; 2022 Jan; 61(1):111-115. PubMed ID: 34879792
[TBL] [Abstract][Full Text] [Related]
7. Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation.
McDonald BA; Vedam S; Yang J; Wang J; Castillo P; Lee B; Sobremonte A; Ahmed S; Ding Y; Mohamed ASR; Balter P; Hughes N; Thorwarth D; Nachbar M; Philippens MEP; Terhaard CHJ; Zips D; Böke S; Awan MJ; Christodouleas J; Fuller CD;
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1606-1618. PubMed ID: 33340604
[TBL] [Abstract][Full Text] [Related]
8. Operating procedures, risk management and challenges during implementation of adaptive and non-adaptive MR-guided radiotherapy: 1-year single-center experience.
Garcia Schüler HI; Pavic M; Mayinger M; Weitkamp N; Chamberlain M; Reiner C; Linsenmeier C; Balermpas P; Krayenbühl J; Guckenberger M; Baumgartl M; Wilke L; Tanadini-Lang S; Andratschke N
Radiat Oncol; 2021 Nov; 16(1):217. PubMed ID: 34775998
[TBL] [Abstract][Full Text] [Related]
9. The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy.
de Mol van Otterloo SR; Christodouleas JP; Blezer ELA; Akhiat H; Brown K; Choudhury A; Eggert D; Erickson BA; Faivre-Finn C; Fuller CD; Goldwein J; Hafeez S; Hall E; Harrington KJ; van der Heide UA; Huddart RA; Intven MPW; Kirby AM; Lalondrelle S; McCann C; Minsky BD; Mook S; Nowee ME; Oelfke U; Orrling K; Sahgal A; Sarmiento JG; Schultz CJ; Tersteeg RJHA; Tijssen RHN; Tree AC; van Triest B; Hall WA; Verkooijen HM
Front Oncol; 2020; 10():1328. PubMed ID: 33014774
[No Abstract] [Full Text] [Related]
10. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments.
Chuong MD; Clark MA; Henke LE; Kishan AU; Portelance L; Parikh PJ; Bassetti MF; Nagar H; Rosenberg SA; Mehta MP; Refaat T; Rineer JM; Smith A; Seung S; Zaki BI; Fuss M; Mak RH
Clin Transl Radiat Oncol; 2023 Jan; 38():161-168. PubMed ID: 36466748
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac.
Eijkelenkamp H; Grimbergen G; Daamen LA; Heerkens HD; van de Ven S; Mook S; Meijer GJ; Molenaar IQ; van Santvoort HC; Paulson E; Erickson BA; Verkooijen HM; Hall WA; Intven MPW
Front Oncol; 2023; 13():1040673. PubMed ID: 37854684
[TBL] [Abstract][Full Text] [Related]
13. MR-guided stereotactic body radiation therapy for primary cardiac sarcomas.
Corradini S; von Bestenbostel R; Romano A; Curta A; Di Gioia D; Placidi L; Niyazi M; Boldrini L
Radiat Oncol; 2021 Mar; 16(1):60. PubMed ID: 33771179
[TBL] [Abstract][Full Text] [Related]
14. Clinical application of MR-Linac in tumor radiotherapy: a systematic review.
Liu X; Li Z; Yin Y
Radiat Oncol; 2023 Mar; 18(1):52. PubMed ID: 36918884
[TBL] [Abstract][Full Text] [Related]
15. Initial clinical experience with magnetic resonance-guided radiotherapy in pediatric patients: Lessons learned from a single institution with proton therapy.
Hall MD; Mittauer KE; Herrera R; Von Werne K; Kotecha R; Kalman NS; McCulloch J; Alvarez D; McAllister NC; Doty DG; Rzepczynski AE; Deere W; Gutierrez AN; Chuong MD
Front Oncol; 2022; 12():1037674. PubMed ID: 36713501
[TBL] [Abstract][Full Text] [Related]
16. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
[TBL] [Abstract][Full Text] [Related]
17. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced: the PUMA trial.
Regnery S; de Colle C; Eze C; Corradini S; Thieke C; Sedlaczek O; Schlemmer HP; Dinkel J; Seith F; Kopp-Schneider A; Gillmann C; Renkamp CK; Landry G; Thorwarth D; Zips D; Belka C; Jäkel O; Debus J; Hörner-Rieber J
Radiat Oncol; 2023 May; 18(1):74. PubMed ID: 37143154
[TBL] [Abstract][Full Text] [Related]
19. Characterization and longitudinal assessment of daily quality assurance for an MR-guided radiotherapy (MRgRT) linac.
Mittauer KE; Dunkerley DAP; Yadav P; Bayouth JE
J Appl Clin Med Phys; 2019 Nov; 20(11):27-36. PubMed ID: 31633882
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implementation and Initial Experience With a 1.5 Tesla MR-Linac for MR-Guided Radiation Therapy for Gynecologic Cancer: An R-IDEAL Stage 1 and 2a First in Humans Feasibility Study of New Technology Implementation.
Lakomy DS; Yang J; Vedam S; Wang J; Lee B; Sobremonte A; Castillo P; Hughes N; Mohammedsaid M; Jhingran A; Klopp AH; Choi S; Fuller CD; Lin LL
Pract Radiat Oncol; 2022; 12(4):e296-e305. PubMed ID: 35278717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
